Trial begins of fourth-generation ICD (implantable cardioverter defibrillator):
This article was originally published in Clinica
French company ELA Medical has begun a US trial of its fourth-generation ICD, the dual chamber DEFENDER IV DR. The device, which was launched in Europe in October, uses an algorithm shown in a recent clinical study to detect more than 90% of atrial arrhythmias. A further improvement on the algorithm increases specificity for atrial fibrillation.
You may also be interested in...
Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.